Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issuance of Notes

23 Mar 2022 07:00

RNS Number : 6780F
GlaxoSmithKline PLC
23 March 2022
 

GlaxoSmithKline plc

Issued: 23 March 2022, London UK

 

 

 

ISSUANCE OF NOTES

 

GSK Consumer Healthcare Capital UK plc and GSK Consumer Healthcare Capital NL B.V. (together with GSK Consumer Healthcare Capital UK plc, the "EMTN Issuers") announce that, on 22 March 2022, they successfully priced the following notes (the "EMTN Notes") under the GBP 10,000,000,000 Euro Medium Term Note Programme of the EMTN Issuers:

- GBP 300,000,000 2.875% Fixed Rate Senior Notes due 2028 and GBP 400,000,000 3.375% Fixed Rate Senior Notes due 2038, each issued by GSK Consumer Healthcare Capital UK plc; and

 

- EUR 850,000,000 1.250% Fixed Rate Notes due 2026, EUR 750,000,000 1.750% Fixed Rate Senior Notes due 2030 and EUR 750,000,000 2.125% Fixed Rate Senior Notes due 2034, each issued by GSK Consumer Healthcare Capital NL B.V.

 

In addition, GSK Consumer Healthcare Capital UK plc and GSK Consumer Healthcare Capital US LLC announce that, on 21 March 2022, they successfully priced the following notes (the "144A Notes") pursuant to an Offering Memorandum dated 21 March 2022:

 

- USD 700,000,000 3.024% Callable Fixed Rate Senior Notes due 2024, USD 300,000,000 Callable Floating Rate Senior Notes due 2024, USD 2,000,000,000 3.375% Fixed Rate Senior Notes due 2027, USD 1,000,000,000 3.375% Fixed Rate Senior Notes due 2029, USD 2,000,000,000 3.625% Fixed Rate Senior Notes due 2032 and USD 1,000,000,000 4.000% Fixed Rate Senior Notes due 2052, each issued by GSK Consumer Healthcare Capital US LLC; and

 

- USD 1,750,000,000 3.125% Fixed Rate Senior Notes due 2025 issued by GSK Consumer Healthcare Capital UK plc.

The EMTN Notes and the 144A Notes (together, the "Notes") will be guaranteed by GlaxoSmithKline plc up to and excluding the Guarantee Assumption Date (as defined in the Terms and Conditions of the Notes).

 

For further information, please contact:

GlaxoSmithKline plc980 Great West RoadBrentfordMiddlesexTW8 9GSUnited Kingdom

UK Media enquiries:

David Mawdsley Simon Steel

Tim Foley

+44 (0) 20 8047 5502

+44 (0) 20 8047 5502

+44 (0) 20 8047 5502

(London)

(London)

(London)

 

 

 

 

European Analyst/Investor enquiries:

James Dodwell

Danielle Smith

+44 (0) 20 8047 2406

+44 (0) 20 8047 0932

(London)

(London)

 

 

IMPORTANT DISCLAIMER: This announcement does not constitute an offer of any securities for sale (including, without limitation, any Notes). The offer and sale of the Notes may be restricted by law in certain jurisdictions.

This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"). The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under the securities laws of any state of the United States, and may not be offered, sold, resold or delivered directly or indirectly, in or into the United States or to a U.S. person absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODDDGDXXSDDGDD
Date   Source Headline
3rd May 20243:30 pmRNSDirector/PDMR Shareholding
1st May 20243:00 pmRNSTotal Voting Rights
1st May 20247:00 amRNS1st Quarter Results
24th Apr 20247:00 amRNSUS FDA accepts new indication filing for Jemperli
19th Apr 20243:30 pmRNSDirector/PDMR Shareholding
17th Apr 20243:30 pmRNSDirector/PDMR Shareholding
17th Apr 20247:05 amRNSGSK announces additional EAGLE-1 results
17th Apr 20247:00 amRNSResults from long-term data relating to Shingrix
16th Apr 20242:11 pmRNSAmendment - Director/PDMR Shareholding
16th Apr 20247:00 amRNSFDA accepts GSK meningitis vaccine candidate file
15th Apr 20243:30 pmRNSDirector/PDMR Shareholding
4th Apr 202412:05 pmRNSReplacement - Total Voting Rights
2nd Apr 20243:00 pmRNSTotal Voting Rights
26th Mar 20243:30 pmRNSDirector/PDMR Shareholding
25th Mar 20241:00 pmRNSNotice of AGM
22nd Mar 20244:20 pmRNSTransfer of Treasury Shares
22nd Mar 20243:36 pmRNSDirector/PDMR Shareholding
18th Mar 20249:30 amRNSNew Phase III Jemperli data in endometrial cancer
13th Mar 20243:48 pmRNSDirector/PDMR Shareholding
8th Mar 20245:12 pmRNSBoard Committee Change
7th Mar 20247:00 amRNSGSK announces positive Blenrep DREAMM-8 results
6th Mar 20244:00 pmRNSViiV LAI vs oral SOC data in adherence-challenged
5th Mar 20245:24 pmRNSGSK Annual Report 2023 on Form 20-F
5th Mar 20247:00 amRNSNew ViiV LA formulation potential 4-month dosing
1st Mar 20243:00 pmRNSTotal Voting Rights
1st Mar 202412:15 pmRNSGSK publishes Annual Report 2023
29th Feb 20247:05 amRNSDirectorate Change
29th Feb 20247:00 amRNSStatement: Zantac (ranitidine) litigation
26th Feb 20243:30 pmRNSDirector/PDMR Shareholding
26th Feb 20247:00 amRNSGSK announces positive EAGLE-1 headline results
22nd Feb 20243:30 pmRNSDirector/PDMR Shareholding
21st Feb 20247:00 amRNSViiV LAI superior to orals in adherence-challenged
20th Feb 20249:01 amRNSJulie Brown - External Appointment
19th Feb 20243:30 pmRNSDirector/PDMR Shareholding
15th Feb 20243:32 pmRNSDirector/PDMR Shareholding
15th Feb 20247:00 amRNSGSK completes acquisition of Aiolos Bio
13th Feb 20244:45 pmRNSDirector/PDMR Shareholding - Replacement
13th Feb 20243:40 pmRNSDirector/PDMR Shareholding
13th Feb 20243:35 pmRNSDirector/PDMR Shareholding
13th Feb 20243:30 pmRNSDirector/PDMR Shareholding
6th Feb 20247:10 amRNSFDA accepts Arexvy filing for adults 50-59 at risk
6th Feb 20247:05 amRNSShingrix 18+ at risk China filing review accepted
6th Feb 20247:00 amRNSGSK presents positive DREAMM-7 phase III data
1st Feb 20243:30 pmRNSDirector/PDMR Shareholding
1st Feb 20243:00 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNSStatement: Zantac (ranitidine) litigation
31st Jan 20247:00 amRNSFinal Results
29th Jan 20247:05 amRNSEMA accepts Arexvy filing for adults 50-59 at risk
29th Jan 20247:00 amRNSEuropean Commission authorises Omjjara in the EU
19th Jan 20243:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.